BioCentury
ARTICLE | Clinical News

Amplimexon imexon regulatory update

January 16, 2006 8:00 AM UTC

EMEA granted Orphan Drug designation to Amplimexon to treat ovarian cancer. The small molecule cyanoaziridine already has U.S. Orphan Drug designation for this indication. ...